Novavax - NVAX Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NVAX shares.
View NVAX analyst ratings or view top-rated stocks.

8 Wall Street analysts have issued 12-month price objectives for Novavax's stock. Their NVAX share price forecasts range from $35.00 to $209.00. On average, they anticipate the company's stock price to reach $162.57 in the next twelve months. This suggests a possible upside of 184.0% from the stock's current price.
View analysts price targets for NVAX or view top-rated stocks among Wall Street analysts.

Novavax's stock was trading at $143.07 at the beginning of 2022. Since then, NVAX stock has decreased by 60.0% and is now trading at $57.25.
View the best growth stocks for 2022 here.

Novavax is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our NVAX earnings forecast.

Novavax, Inc. (NASDAQ:NVAX) issued its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($4.31) earnings per share for the quarter, missing the consensus estimate of ($4.04) by $0.27. The biopharmaceutical company earned $178.80 million during the quarter, compared to the consensus estimate of $347.34 million. Novavax had a negative net margin of 93.91% and a negative trailing twelve-month return on equity of 572.54%. The firm's quarterly revenue was up 13.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($3.21) EPS.

Novavax shares reverse split before market open on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Novavax issued an update on its FY 2022 earnings guidance on Monday, June, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $4.00 billion-$5.00 billion, compared to the consensus revenue estimate of $4.49 billion.

46 employees have rated Novavax Chief Executive Officer Stanley C. Erck on Glassdoor.com. Stanley C. Erck has an approval rating of 71% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Palo Alto Networks (PANW), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Novavax's stock is owned by a number of retail and institutional investors. Top institutional investors include IMC Chicago LLC (0.00%), Candriam S.C.A. (0.17%), Van ECK Associates Corp (0.14%), Wolverine Asset Management LLC (0.00%), State Board of Administration of Florida Retirement System (0.11%) and Banco Bilbao Vizcaya Argentaria S.A. (0.09%). Insiders that own company stock include David M Mott, Gary C Evans, Gregory M Glenn, Gregory M Glenn, James F Young, John A Herrmann III, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck.
View institutional ownership trends.

Shares of NVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVAX stock can currently be purchased for approximately $57.25.

Novavax (NASDAQ:NVAX) has a market capitalization of $4.47 billion and generates $1.15 billion in revenue each year. The biopharmaceutical company earns $-1,743,750,000.00 in net income (profit) each year or ($17.68) on an earnings per share basis.

Novavax employs 1,541 workers across the globe.

Novavax was founded in 1987.

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The official website for the company is www.novavax.com. The biopharmaceutical company can be reached via phone at (240) 268-2000, via email at ir@novavax.com, or via fax at 240-268-2100.